黄芪注射液对糖尿病肾病患者血小板活化功能的影响

Effect of astragalus on platelet activation of diabetic nephropathy

目的:探讨糖尿病肾病(DN)患者血小板活化功能的变化及黄芪对其的影响。方法:23例肾病综合征患者随机分为两组,A组12例进行常规治疗;B组11例在常规治疗基础上给予黄芪注射液40 g(20 mL)/d静脉滴注,疗程为15 d。治疗前、后应用流式细胞仪测定外周血血小板CD62P及血小板膜Fg含量,并以10例健康人作对照。结果:糖尿病肾病患者血小板CD62P及血小板膜Fg含量均显著高于健康人(P<0.01);治疗后显著低于治疗前(P<0.01),治疗后B组低于A组(P<0.01)。结论:糖尿病肾病患者血小板活化程度在其发病中起一定作用,黄芪注射液能有效降低糖尿病肾病患者血小板活化功能。

Objective： To study the change of platelet activation of diabetic nephropathy（DN） and the effect of astragalus injection on it. Methods： Twenty-three patients with nephropathy syndrome were randomly divided into two groups; patients in group A（n = 12） was treated by conventional therapy; patients in group B（n = 11） was treated by conventional therapy and astragalus injection. The astragalus injection used for patients in group B was 40g （20 mL） daily, infused intravenously for 15 days. The therapeutic course in both groups were 15days. CD62P of platelet and Fg of platelet membrane in peripheral blood were examined using flow cytometric analysis before and after treatment respectively, which was compared with 10 healthy subjects as control. Results： CD62P and Fg in paitents with DN were higher significantly than those in control group（ P 〈 0.01 ）; CD62P and Fg decreased markedly after treatment , compared with before treatment, there was significant difference （ P 〈 0.01 ） ; CD62P and Fg in group B were significantly lower than those in group A after treatment（P〈0.01 ）. Conclusion： These results suggest that the level of activated platelet activation may be involved in the pathogenesis of DN and astragalus can decrease platelet activation of patients with DN effectivly.